Abstract
In the early days of cancer chemotherapy compounds which showed promising antitumour effects in the laboratory were rapidly given to patients with a minimum of preclinical testing. The subsequent clinical evaluation of toxicity and efficacy was often crude and superficial by today’s standards. Stimulated by events such as the thalidomide tragedy, increasing statutory controls on new drug development were introduced during the 1950s and 1960s. During the same period the principles of clinical assessment became more clearly defined and a relatively uniform pattern of evaluation has emerged.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Antineoplastic agents and FDA regulations: square pegs for round holes. Wittes RE (1987) Cancer Treatment Reports, 71: 795–806
Drug development at the National Cancer Institute: a historical perspective. Zubrod CG in Fundamentals of Cancer Chemotherapy (Eds. Hellman S, Carter SK) McGraw Hill, New York, 1987, pp 101–110
Symposium on -methodology and quality assurance in clinical trials. Various authors (1985) Cancer Treatment Reports, 69: 1039–1230
Anti-cancer drugs 5: Phase I trials. Calvert AH, Balmanno K (1987) Cancer Topics, 6: 51–52
Anti-cancer drugs 6: The design of phase II trials. Newlands E (1987) Cancer Topics, 6: 63–65
Anti-cancer drugs 7: Phase III and IV trials. Foster BJ (1987) Cancer Topics, 6: 87–89
Clinical evaluation of antitumour therapy Muggia FM, Rozencweig M (editors). Martinus Nijhoff, Boston, 1987
Illusion and reality: practical pitfalls in interpreting clinical trials. Glatstein E, Makuch RW (1984) Journal of Clinical Oncology, 2: 488–497
The effect of measuring error on the results of therapeutic trials in advanced cancer. Moertel CG, Homey JA (1976) Cancer, 38: 388–398
Measurement of the quality of life after cancer treatment. Selby P (1985) British Journal of Hospital Medicine, 33: 266–271
Measuring and analysing quality of life in cancer clinical trials: a review. Fayers PM, Jones DR (1983) Statistics in Medicine, 2: 429–446
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Priestman, T.J. (1989). The Development and Assessment of New Cytotoxic Drugs. In: Cancer Chemotherapy: an Introduction. Springer, London. https://doi.org/10.1007/978-1-4471-1686-8_9
Download citation
DOI: https://doi.org/10.1007/978-1-4471-1686-8_9
Publisher Name: Springer, London
Print ISBN: 978-3-540-19551-1
Online ISBN: 978-1-4471-1686-8
eBook Packages: Springer Book Archive